W
WAVEMAN · COMPANY
SLSN · Solesence, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

SLSN

SOLESENCE, INC.
PHARMA & BIOTECH · PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS · CIK 0000883107
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
25
13F, latest reported quarter
REVENUE GROWTH
+18.6%
XBRL, annual
NET MARGIN
2.9%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
25 funds added or opened last quarter
below 67% of Pharma & Biotech
REVENUE
+18.6% year over year
more than 67% of Pharma & Biotech
MARGIN
2.9% net margin
more than 71% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
25 funds added or opened positions in the latest 13F quarter, of 46 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -74.9%
-74.9%12M
-82%-48%-14%+20%2025-092025-102025-122026-032026-052026-072026-09 2025-11-14 · WHITMORE R JANET bought $34.2K2025-11-19 · WHITMORE R JANET bought $9.8K2025-11-19 · WHITMORE R JANET bought $9.4K2025-11-17 · WHITMORE R JANET bought $9.3K2025-12-24 · WHITMORE R JANET bought $2.9K2025-12-24 · WHITMORE R JANET bought $1.9K2025-11-18 · WHITMORE R JANET bought $489
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows 25 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for SOLESENCE, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
WHITMORE R JANET
Director
BUY
2025-12-24
1,000.0
$1.9K
WHITMORE R JANET
Director
BUY
2025-12-24
1,500.0
$2.9K
WHITMORE R JANET
Director
BUY
2025-11-19
5,000.0
$9.8K
WHITMORE R JANET
Director
BUY
2025-11-19
5,000.0
$9.4K
WHITMORE R JANET
Director
BUY
2025-11-18
267.0
$489
11 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 6 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
VANGUARD CAPITAL MANAGEMENT LLC
830,508.0 sh
$610.4K
BlackRock, Inc.
463,652.0 sh
$340.8K
Bank of New York Mellon Corp
317,609.0 sh
$233.4K
MILLENNIUM MANAGEMENT LLC
276,497.0 sh
$203.2K
GEODE CAPITAL MANAGEMENT, LLC
238,514.0 sh
$175.4K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
iShares Micro-Cap ETF
$46.7K POSITION · AS OF 2026-03-31
0.0%
1290 VT Micro Cap Portfolio
$3.6K POSITION · AS OF 2026-03-31
0.0%
Small Cap Index Fund
$22.5K POSITION · AS OF 2026-03-31
0.0%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND
$22.7K POSITION · AS OF 2026-02-28
0.0%
Fidelity Small Cap Growth Index Fund
$14.2K POSITION · AS OF 2026-03-31
0.0%
iShares Russell 2000 Growth ETF
$133.8K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$62.1M$52.3M$37.3M$37.3M
GROSS PROFIT$16.1M$16.2M$7.8M$8.4M
OPERATING INCOME$1.6M$5.1M$-3.5M$-2.3M
NET INCOME$1.8M$4.2M$-4.4M$-2.6M
EPS (DILUTED)0.020.07-0.09-0.05
OPERATING CASH FLOW$-8.6M$2.0M$-2.0M$-1.6M
CASH$1.3M$1.4M$1.7M$2.2M
LONG-TERM DEBT$1.0M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →